Webb7 apr. 2024 · Shanghai Vinnerna Biosciences Co., Ltd. ClinicalTrials.gov Identifier: NCT05802810 Other Study ID Numbers: JT016-001-I : First Posted: April 7, 2024 Key Record Dates: Last Update Posted: April 7, 2024 Last Verified: February 2024 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Webb30 jan. 2024 · The other new drug, VV116, was jointly developed by Shanghai Vinnerna Biosciences and other research institutes in Shanghai. The administration said that the two oral pills will be used for mild and moderate COVID-19 adult patients.
迈威生物 - 探索生命，惠及健康
WebbShanghai Vinnerna Biosciences Co., Ltd. Sponsor GmbH. 2024-02-03. OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA. Duration of Hospitalization. Clinical Manifestation of COVID-19. Remdesivir. Favipiravir. Bernadette Dian Novita, MD.,PhD. WebbFor research use only. VV116, a promising orally administered anti-SARS-CoV-2 nucleoside drug candidate, exerts functions by targeting the viral RNA-dependent RNA polymerase through its nucleoside triphosphate form with an IC50 of 0.67±0.24 μM. CAS No. 2647442-33-7 (free base) Purity & Quality Control Batch: E111101 Purity: 98.95% fisher lacrosse
Efficacy and Safety of JT001 (VV116) Compared With Favipiravir
Webb15 mars 2024 · Shanghai Vinnerna Biosciences Co., Ltd. ClinicalTrials.gov Identifier: NCT05279235 Other Study ID Numbers: JT001-006-III-COVID-19 : First Posted: March … Webb5 aug. 2024 · Shanghai Vinnerna Biosciences Co., Ltd. (Industry) Overall Status. Recruiting. CT.gov ID ... real-world study to review outcomes of Mild to Moderate COVID-19 patients admitted to Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine (hereinafter referred to as Ruijin Hospital) ... Webb2 maj 2024 · Shanghai Vinnerna Biosciences Co., Ltd. ClinicalTrials.gov Identifier: NCT05355077 Other Study ID Numbers: JT001-005-I : First Posted: May 2, 2024 Key … fisher laboratory products